Pharma Commercial Mock
← All views·CI feed·API docs
AASCO
Meeting Library
ASCO Annual Meeting 2026 · Chicago, IL
7 shown of 6,399 total abstracts
  1. Abstract 99672026-06-05 · 14:45 CT · Arie Crown Theater
    Long-term follow-up of Opdivo 2L for metastatic melanoma: CheckMate-763
    M.C. Garassino, H. Rugo, J. Brahmer, et al. · Chinese University of Hong Kong
    Education SessionMelanoma📄🖼️
  2. Abstract 102632026-06-03 · 14:30 CT · S406
    Long-term follow-up of Keytruda neoadjuvant for metastatic melanoma: KEYNOTE-765
    G. Curigliano, R. Herbst, L. Paz-Ares, et al. · Mayo Clinic
    Education SessionMelanoma📄🖼️
  3. Abstract 97342026-06-04 · 21:45 CT · S100A
    Biomarker subgroup analysis of Opdivo in metastatic melanoma (the CheckMate-871 study)
    N. Rizvi, S. Antonia, M. Krop, et al. · University of Chicago
    Education SessionMelanoma📄🖼️
  4. Abstract 95952026-06-05 · 15:00 CT · E450
    Biomarker subgroup analysis of Opdivo in metastatic melanoma (the CheckMate-662 study)
    F. Andre, S. Modi, E. Winer · Mayo Clinic
    Education SessionMelanoma📄🖼️
  5. Abstract 96242026-06-05 · 13:15 CT · Arie Crown Theater
    Long-term follow-up of Opdivo maintenance for metastatic melanoma: CheckMate-695
    J. Cortes, F. Andre, J. Brahmer, et al. · Vall d'Hebron Institute of Oncology
    Education SessionMelanoma📄🖼️
  6. Abstract 96072026-06-04 · 15:00 CT · Hall B1
    KEYNOTE-930: Keytruda (pembrolizumab) maintenance in metastatic melanoma
    E. Winer, G. Curigliano, H. Rugo, et al. · Cleveland Clinic
    Education SessionMelanoma📄🖼️
  7. Abstract 96782026-06-04 · 19:45 CT · S406
    KEYNOTE-252: Keytruda (pembrolizumab) neoadjuvant in metastatic melanoma
    F. Andre, M.C. Garassino, J. Brahmer, et al. · Memorial Sloan Kettering Cancer Center
    Education SessionMelanoma📄🖼️
© 2026 American Society of Clinical Oncology · Citations follow JCO supplement format:J Clin Oncol 44, 2026 (suppl 17; abstr XXXX). Demo mock.